Cytosorbents (CTSO) Asset Writedowns and Impairment (2016 - 2026)
Cytosorbents (CTSO) reported Asset Writedowns and Impairment of $300000.0 for Q1 2026, up 3650.0% on a YoY basis from $8000.0 in Q1 2025, and up 320.59% quarter-over-quarter from -$136000.0 in Q4 2025.
Cytosorbents (CTSO) Asset Writedowns and Impairment (2016 - 2026) Analysis & Trends
Cytosorbents has reported Asset Writedowns and Impairment for 11 years, with the latest figure at $300000.0 in Q1 2026.
- For the quarter ending Q1 2026, Asset Writedowns and Impairment rose 3650.0% year-over-year to $300000.0; the trailing twelve-month figure through Mar 2026 stood at $332000.0 (up 465.55% YoY), and the FY2025 full-year result was $40000.0, down 65.22% from the prior year.
- Asset Writedowns and Impairment for Q1 2026 stood at $300000.0, up from -$136000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $462237.0 in Q3 2023, with the low at -$421057.0 in Q3 2022.
- Historically, Asset Writedowns and Impairment has averaged $64843.0 across 5 years, with a median of $64296.0 in 2024.
- Annual changes were most pronounced in 2022 — Asset Writedowns and Impairment plunged 6960.96% — and 2026, when it soared 3650.0%.
- Cytosorbents' Asset Writedowns and Impairment stood at -$18723.0 in 2022, then surged by 1061.73% to $180064.0 in 2023, then tumbled by 95.56% to $8000.0 in 2024, then tumbled by 1800.0% to -$136000.0 in 2025, then soared by 320.59% to $300000.0 in 2026.
- The last three Asset Writedowns and Impairment figures came in at $300000.0 (Q1 2026), -$136000.0 (Q4 2025), and $167000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn |
| 10 | Cytosorbents | 25.72 Mn | 20.92 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | -136,000.00 |
| Dec 31, 2025 | -136,000.00 |
| Sep 30, 2025 | 167,000.00 |
| Sep 30, 2025 | 167,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Mar 31, 2025 | 8,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | 78,000.00 |
| Sep 30, 2024 | 78,000.00 |
| Jun 30, 2024 | -35,296.00 |
| Jun 30, 2024 | -35,296.00 |
| Mar 31, 2024 | 64,296.00 |
| Mar 31, 2024 | 64,296.00 |
| Dec 31, 2023 | 180,064.00 |
| Dec 31, 2023 | 180,064.00 |